<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="correction"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10729651</article-id><article-id pub-id-type="doi">10.3390/ph16121685</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-16-01685</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Vassallo et al. Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins. <italic toggle="yes">Pharmaceuticals</italic> 2023, <italic toggle="yes">16</italic>, 1429</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6891-9724</contrib-id><name><surname>Vassallo</surname><given-names>Valentina</given-names></name><xref rid="af1-pharmaceuticals-16-01685" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Meo</surname><given-names>Celeste</given-names></name><xref rid="af1-pharmaceuticals-16-01685" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8560-721X</contrib-id><name><surname>Toro</surname><given-names>Giuseppe</given-names></name><xref rid="af2-pharmaceuticals-16-01685" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3659-0415</contrib-id><name><surname>Alfano</surname><given-names>Alberto</given-names></name><xref rid="af1-pharmaceuticals-16-01685" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0976-925X</contrib-id><name><surname>Iolascon</surname><given-names>Giovanni</given-names></name><xref rid="af2-pharmaceuticals-16-01685" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1066-843X</contrib-id><name><surname>Schiraldi</surname><given-names>Chiara</given-names></name><xref rid="af1-pharmaceuticals-16-01685" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-16-01685" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-16-01685"><label>1</label>Department of Experimental Medicine, Section of Biotechnology, University of Campania &#x0201c;Luigi Vanvitelli&#x0201d;, 80138 Naples, Italy; <email>valentina.vassallo@unicampania.it</email> (V.V.); <email>celeste.dimeo@unicampania.it</email> (C.D.M.); <email>alberto.alfano@unicampania.it</email> (A.A.)</aff><aff id="af2-pharmaceuticals-16-01685"><label>2</label>Department of Medical and Surgical Specialties and Dentistry, University of Campania &#x0201c;Luigi Vanvitelli&#x0201d;, 80138 Naples, Italy; <email>giuseppe.toro@unicampania.it</email> (G.T.); <email>giovanni.iolascon@unicampania.it</email> (G.I.)</aff><author-notes><corresp id="c1-pharmaceuticals-16-01685"><label>*</label>Correspondence: <email>chiara.schiraldi@unicampania.it</email>; Tel.: +39-0815667546</corresp></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>12</month><year>2023</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>16</volume><issue>12</issue><elocation-id>1685</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" id="ra1-pharmaceuticals-16-01685" xlink:href="10.3390/ph16101429" vol="16" page="1429"/></article-meta></front><body><p>In the original publication [<xref rid="B1-pharmaceuticals-16-01685" ref-type="bibr">1</xref>], there were mistakes in Figure 1 caption and the location of some software companies. </p><sec><title>1. Error in Figure 1 Caption</title><p>Chondroitin sulfated should be <bold>chondroitin sulfate</bold>.</p><p>The corrected <bold>&#x0201c;Figure 1 caption&#x0201d;</bold> appears below.</p><p>Figure 1. Mechanical spectra of the preparations as commercialized. HHA + CS + cd: hyaluronic acid sodium salt 2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), marine chondroitin sulfate 2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), and cyclodextrins 1% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>); HHA/BC: hyaluronic acid sodium salt 2.4% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>) and unsulfated chondroitin 1.6% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>).</p></sec><sec><title>2. Errors in Software Company Locations</title><p>IBSA Farmaceutici (Lodi, CA, USA) should be <bold>IBSA Farmaceutici, Lodi, Italy;</bold> Kolinpharma (Lodi, CA, USA) (Kolinpharma) should be <bold>Kolinpharma, Milan, Italy;</bold> BD Falcon (BD, Falcon, USA) should be <bold>BD, Falcon, Franklin Lakes, NJ, USA;</bold> Bio-Rad (Beckman, Milano, Italy) should be <bold>Beckman, Milan, Italy;</bold> Company (Bio-Rad, Milan, Laboratories) should be <bold>Bio-Rad Laboratories, Milan, Italy;</bold> Thermo Fisher Scientific (ThermoFisher Scientific, USA) should be <bold>Thermo Fisher Scientific, Waltham, MA, USA.</bold></p><p>The corrected contents appears below.</p><p><bold>Paragraphs 1 and 2 of Section 4.1<italic toggle="yes">. Class III Medical Device Based on HA and CS or BC</italic></bold>:</p><p>Sinogel<sup>&#x000ae;</sup> 3 mL (IBSA Farmaceutici, Lodi, Italy) (here referred to as HHA/BC) was kindly provided by IBSA Farmaceutici Italia.</p><p>Dolatrox<sup>&#x000ae;</sup> (Kolinpharma, Milan, Italy) (here referred to as HHA + CS + cd) was bought in a pharmacy; it is reported to contain hyaluronic acid sodium salt 2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), chondroitin sulfate 2% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>), and cyclodextrins 1% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>).</p><p><bold>Paragraphs 1 of Section 4.4<italic toggle="yes">. OA In Vitro Model Setup</italic></bold>:</p><p>The next day, the cell suspension was filtered (70 &#x003bc;m, BD Falcon, Franklin Lakes, NJ, USA), centrifuged at 1500 rpm for 7 min (Eppendorf Centrifuge), washed with PBS, and re-centrifuged.</p><p><bold>Paragraphs 1 of Section 4.5<italic toggle="yes">. Cellular Viability Assay</italic></bold>:</p><p>The optical densities of the supernatants were measured at 450 nm using a Beckman DU 640 spectrometer (Beckman, Milan, Italy) after specific treatments and incubation with a cell counting solution.</p><p><bold>Paragraphs 1 of Section 4.6<italic toggle="yes">. Gene Expression Analyses via qRT-PCR</italic></bold>:</p><p>The variation of gene expression was calculated by normalizing the data about GAGs treated cells with respect to pCTRL, applying the Livak method (2<sup>&#x02212;&#x00394;&#x00394;Ct</sup>) [55] and using Bio-Rad iQ&#x02122;5 Optical System Software, Version 2.1 (Bio-Rad Laboratories, Milan, Italy).</p><p><bold>Paragraphs 1 of Section 4.7. <italic toggle="yes">Protein Analyses via Western Blotting</italic></bold>:</p><p>Primary chondrocytes were seeded in a 12-well standard plate (BD Falcon, Franklin Lakes, NJ, USA) (30 &#x000d7; 10<sup>3</sup> cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAGs-based gels for 7 days at a final concentration in the culture medium of 4 mg/mL.</p><p><bold>Paragraphs 1 of Section 4.8. <italic toggle="yes">Immunofluorescence Analyses</italic></bold>:</p><p>To analyze the protein expression of COLII via immunofluorescence staining (IF), primary chondrocytes were seeded in a chamber slide (BD Falcon, Franklin Lakes, NJ, USA) (5 &#x000d7; 10<sup>3</sup> cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAG-based medical devices (4 mg/mL) for 24 h.</p><p>Then, the slices were incubated with a FITC-conjugated goat anti-rabbit secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA) (diluted 1:200) for 1 h at room temperature and covered using the mounting medium with DAPI-aqueous.</p><p><bold>Paragraphs 1 of Section 4.9<italic toggle="yes">. ELISA Assay</italic></bold>:</p><p>Each experiment was performed in triplicate, and the cytokine was quantified by a microplate reader (Bio-Rad Laboratories, Milan, Italy).</p><p>The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><ref-list><title>Reference</title><ref id="B1-pharmaceuticals-16-01685"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassallo</surname><given-names>V.</given-names></name>
<name><surname>Di Meo</surname><given-names>C.</given-names></name>
<name><surname>Toro</surname><given-names>G.</given-names></name>
<name><surname>Alfano</surname><given-names>A.</given-names></name>
<name><surname>Iolascon</surname><given-names>G.</given-names></name>
<name><surname>Schiraldi</surname><given-names>C.</given-names></name>
</person-group><article-title>Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>1429</elocation-id><pub-id pub-id-type="doi">10.3390/ph16101429</pub-id><pub-id pub-id-type="pmid">37895900</pub-id>
</element-citation></ref></ref-list></back></article>
